Patents by Inventor Patrick Roussel

Patrick Roussel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190105367
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 11, 2019
    Applicant: Emergent Product Development Gaithersburg Inc.
    Inventors: Jutta HEIM, Peter SCHNEIDER, Patrick ROUSSEL, Daniel MILLIGAN, Christian BARTELS, Glenn DALE
  • Patent number: 10155021
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 18, 2018
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
  • Publication number: 20180327723
    Abstract: The invention relates to methods for producing glycosylated nootkatol. In particular, a recombinant host comprising a gene encoding a UDP-glycosyltransferase polypeptide capable of glycosylating nootkatol is disclosed. Glycosylation of nootkatol detoxifies nootkatol, allowing for greater production of (glycosylated-)nootkatol, a precursor of nootkatone, and therefore greater production of nootkatone. The invention also relates to methods of converting non-toxic, glycosylated nootkatol produced by a recombinant host to nootkatol, wherein the nootkatol can subsequently be converted to large quantities of nootkatone to be used in flavorings, perfumes, and/or insect repellents.
    Type: Application
    Filed: November 14, 2016
    Publication date: November 15, 2018
    Inventors: Dayal Saran, Jorgen Hansen, Philippe Prochasson, Patrick Roussel, Laura Occhipinti, Alexei Ouspenski, Sumire Honda Malca
  • Publication number: 20180296555
    Abstract: Disclosed herein are compounds of Formula I wherein R1, R2, X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Patrick ROUSSEL, Jutta HEIM, Peter SCHNEIDER, Christian BARTELS, Yaoquan LIU, Glenn DALE, Daniel MILLIGAN
  • Publication number: 20180209262
    Abstract: Method for characterizing subterranean formation is described. One method includes inducing one or more fractures in a portion of the subterranean formation. Determining a poroelastic pressure response due to the inducing of the one or more fractures. The poroelastic pressure response is measured by a sensor that is in at least partial hydraulic isolation with the portion of the subterranean formation. Monitoring closure of the one or more fractures via the poroelastic pressure response.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Nicolas Patrick ROUSSEL, Horacio FLOREZ, Adolfo Antonio RODRIGUEZ, Samarth AGRAWAL
  • Patent number: 9988895
    Abstract: Method for characterizing subterranean formation is described. One method includes: placing a subterranean fluid into a well extending into at least a portion of the subterranean formation to induce one or more fractures; measuring pressure response via one or more pressure sensors installed in the subterranean formation; and determining a physical feature of the one or more fractures.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: June 5, 2018
    Assignee: CONOCOPHILLIPS COMPANY
    Inventors: Nicolas Patrick Roussel, Horacio Florez, Adolfo Antonio Rodriguez, Samarth Agrawal
  • Publication number: 20170232060
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Application
    Filed: June 23, 2016
    Publication date: August 17, 2017
    Inventors: Jutta HEIM, Peter SCHNEIDER, Patrick ROUSSEL, Daniel MILLIGAN, Christian BARTELS, Glenn DALE
  • Publication number: 20170209437
    Abstract: Disclosed herein are compounds of Formula I wherein R1, R2, X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Inventors: Patrick ROUSSEL, Jutta HEIM, Peter SCHNEIDER, Christian BARTELS, Yaoquan LIU, Glenn DALE, Daniel MILLIGAN
  • Publication number: 20170106045
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Application
    Filed: June 23, 2016
    Publication date: April 20, 2017
    Inventors: Jutta HEIM, Peter SCHNEIDER, Patrick ROUSSEL, Daniel MILLIGAN, Christian BARTELS, Glenn DALE
  • Patent number: 9403818
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: August 2, 2016
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
  • Patent number: 9346799
    Abstract: A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a ?-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another ?-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: May 24, 2016
    Assignee: Basilea Pharmaceuticals AG
    Inventors: Eric Desarbre, Bérangère Gaucher, Malcom G. P. Page, Patrick Roussel
  • Publication number: 20160122320
    Abstract: A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a ?-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another ?-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Inventors: Eric Desarbre, Bérangère Gaucher, Malcom G.P. Page, Patrick Roussel
  • Patent number: 9133219
    Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 15, 2015
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
  • Publication number: 20150176394
    Abstract: Method for characterizing subterranean formation is described. One method includes: placing a subterranean fluid into a well extending into at least a portion of the subterranean formation to induce one or more fractures; measuring pressure response via one or more pressure sensors installed in the subterranean formation; and determining a physical feature of the one or more fractures.
    Type: Application
    Filed: December 18, 2014
    Publication date: June 25, 2015
    Inventors: Nicolas Patrick ROUSSEL, Horacio FLOREZ, Adolfo Antonio RODRIGUEZ
  • Publication number: 20150141435
    Abstract: Disclosed herein are compounds of Formula I wherein R1, R2, X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 21, 2015
    Inventors: Patrick ROUSSEL, Jutta HEIM, Peter SCHNEIDER, Christian BARTELS, Yaoquan LIU, Glen DALE, Daniel MILLIGAN
  • Publication number: 20150080373
    Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
  • Patent number: 8962842
    Abstract: Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: February 24, 2015
    Assignee: Evolva SA
    Inventors: Patrick Roussel, Jutta Heim, Peter Schneider, Christian Bartels, Yaoquan Liu, Glen Dale, Daniel Milligan
  • Publication number: 20150031662
    Abstract: A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a ?-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another ?-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).
    Type: Application
    Filed: October 13, 2014
    Publication date: January 29, 2015
    Inventors: Eric Desarbre, Bérangère Gaucher, Malcom G.P. Page, Patrick Roussel
  • Patent number: 8927542
    Abstract: The antibacterial compound of formula I wherein X1, X3; X4 and X6, each independently of the others, represents a nitrogen atom or CR2, with the proviso that at least one of X1, X3; X4 and X6 represents a nitrogen atom; X2 represents C—H, C—(C1-C6alkyl), C—(C1-C6alkoxy), C-halogen, C—COOH; X5 represents C—H or C—(C1-C6alkyl), C-halogen; A1, A2, A3, R1 and R4 represent various substituents, G represents aryl or heteroaryl, which is unsubstituted or substituted which compounds show good activity against pathogenic bacteria.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 6, 2015
    Assignee: Basilea Pharmaceutica AG
    Inventors: Berangere Gaucher, Franck Hubert Danel, Patrick Roussel
  • Patent number: 8901293
    Abstract: New monobactam antibiotics compounds which contain an 3-amino-azetidin-2-one ring and are active against gram-negative bacteria, wherein the compounds include the compound 2-(2-amino-thiazol-4-yl)-2-[(Z)-(1H,4H-1,5-dihydroxy-4-oxo-pyridin-2-yl)methoxyimino]-N-[3(S)-1-oxysulfonyl-2,2-dimethyl-4-oxo-azetidin-3-yl]acetamide.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: December 2, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Eric Desarbre, Bérangére Gaucher, Malcolm G. P. Page, Patrick Roussel